While investors should generally focus on compelling long-term ideas, sometimes, there’s a little bit of room for speculation. That might be the case for Kura Oncology (KURA), which presents a tempting proposition. Currently, KURA stock is caught between excited investors who anticipate a continued rally and those who have become increasingly skeptical.
Both sides have their arguments. On the surface, KURA stock appears a relevant idea. Specializing in cancer research, the company focuses on developing precision medicines or therapies that take aim at specific genetic alterations or molecular pathways that spark cancer growth and progression.
